摘要
目的观察二地降糖丸治疗2型糖尿病的临床疗效并作安全性评价。方法将符合纳入标准的90例患者随机分为治疗组与对照组各45例;对照组口服格列喹酮、二甲双胍治疗,治疗组在对照组基础上加服二地降糖丸。结果治疗组总有效率明显优于对照组(P<0.05),且治疗组在降低空腹血糖、餐后2 h血糖及糖化血红蛋白水平方面明显优于对照组(P<0.05或P<0.01)。结论二地降糖丸治疗2型糖尿病安全有效,无毒副作用。
Objective To observe clinical efficacy in treating type-2 diabetes with Erdijiangtangwan and conduct the safety assessment. Methods A total of 90 eases meeting choice criteria were randomly divided into the treatment group of 45 eases and the control group of 45 cases. The control group was subject to the oral administration of gliquidone and metformin, and the treatment group was subject to gliquidone, metformin and Erdijiangtangwan. Results The treatment group was sig- nificantly better than the control group in the total efficiency （P 〈 0.05）; more, the treatment group was significantly better than the eontrol group in reduction of fasting blood glucose, 2-hour postprandial blood glucose and glyeosylated hemoglobin levels （P 〈 0.05 or P 〈 0.01）. Conclusion Erdijiangtangwan is safe, effective and non-toxic in treatment of type 2 diabetes.
出处
《中国现代医生》
2012年第26期77-78,80,共3页
China Modern Doctor
